109 related articles for article (PubMed ID: 3065926)
1. In vitro selection of Escherichia coli mutants with decreased susceptibility to norfloxacin.
Forsgren A; Striby AC
Scand J Infect Dis; 1988; 20(5):531-4. PubMed ID: 3065926
[TBL] [Abstract][Full Text] [Related]
2. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
Smith JT
Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
[TBL] [Abstract][Full Text] [Related]
3. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
Vuye A
Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
[TBL] [Abstract][Full Text] [Related]
4. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
Tenney JH; Maack RW; Chippendale GR
Antimicrob Agents Chemother; 1983 Jan; 23(1):188-9. PubMed ID: 6219620
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.
Hirai K; Aoyama H; Suzue S; Irikura T; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1986 Aug; 30(2):248-53. PubMed ID: 3532944
[TBL] [Abstract][Full Text] [Related]
6. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
Linde HJ; Lehn N
J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.
Moniot-Ville N; Guibert J; Moreau N; Acar JF; Collatz E; Gutmann L
Antimicrob Agents Chemother; 1991 Mar; 35(3):519-23. PubMed ID: 2039202
[TBL] [Abstract][Full Text] [Related]
8. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
Croize J; Le Noc P; Bryskier A; Robert J
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of and resistance to ciprofloxacin.
Hooper DC; Wolfson JS; Ng EY; Swartz MN
Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
[TBL] [Abstract][Full Text] [Related]
10. In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid.
Piffaretti JC; Demarta A; Leidi-Bulla L; Peduzzi R
Eur J Clin Microbiol; 1983 Dec; 2(6):600-1. PubMed ID: 6230227
[No Abstract] [Full Text] [Related]
11. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.
Hooper DC; Wolfson JS; Souza KS; Tung C; McHugh GL; Swartz MN
Antimicrob Agents Chemother; 1986 Apr; 29(4):639-44. PubMed ID: 3010850
[TBL] [Abstract][Full Text] [Related]
12. The mode of action of 4-quinolones and possible mechanisms of resistance.
Smith JT
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():21-9. PubMed ID: 3542946
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Cohen SP; McMurry LM; Hooper DC; Wolfson JS; Levy SB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1318-25. PubMed ID: 2679373
[TBL] [Abstract][Full Text] [Related]
14. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Guimaraes MA; Noone P
J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
[TBL] [Abstract][Full Text] [Related]
15. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
[TBL] [Abstract][Full Text] [Related]
16. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
17. [Role of double strand DNA break repair for quinolone sensitivity in Escherichia coli: therapeutic implications].
González-Soltero R; García-Cañas A; Mohedano RB; Mendoza-Chamizo B; Botello E
Rev Esp Quimioter; 2015 Jun; 28(3):139-44. PubMed ID: 26032998
[TBL] [Abstract][Full Text] [Related]
18. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
Tavío MM; Vila J; Ruiz J; Ruiz J; Martín-Sánchez AM; Jiménez de Anta MT
J Antimicrob Chemother; 1999 Dec; 44(6):735-42. PubMed ID: 10590273
[TBL] [Abstract][Full Text] [Related]
20. Positive R plasmid mutator effect on chromosomal mutation to nalidixic acid resistance in nalidixic acid-exposed cultures of Escherichia coli.
Ambler JE; Pinney RJ
J Antimicrob Chemother; 1995 May; 35(5):603-9. PubMed ID: 7592173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
